Biohaven's BHV-0223 meets in Phase II/III for speaking anxiety

Biohaven Pharmaceuticals Holding Co. Ltd. (NYSE:BHVN) said BHV-0223 met the primary endpoint of reducing anxiety while performing an anxiety-provoking speech task vs.

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE